Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GNT-0003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Genethon/Hansa Start Phase 2 Trial Of Imlifidase Pre-Treatment for Crigler-Najjar
Details : GNT-0003 is being developed for crigler-najjar syndrome. The drug candidate is administered through intravenous route. Direct administration of an AAV vector carrying a normal copy of UGT1A1.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : GNT-0003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imlifidase
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 24, 2024
Lead Product(s) : Imlifidase
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Results Of Gene Therapy GNT0004 for Duchenne Muscular Dystrophy Presented
Details : GNT0004 is an AAV8 vector-based gene therapy containing a shortened version of the DMD gene encoding dystrophin, targeting treatment for patients with Duchenne muscular dystrophy.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GNT-003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GNT-0003 is being developing a gene therapy treatment to treat patients with severe forms of CN syndrome by restoring expression of the UGT1A1 enzyme in the patient’s liver.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : GNT-003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Recipient : Centre d'Etude des Cellules Souches
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Recipient : Centre d'Etude des Cellules Souches
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CDMO’s capacity to produce AAV materials at large-scale will support Genethon and Sarepta’s project to take micro-dystrophin to clinical trials this year.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 01, 2020
Lead Product(s) : GNT0004
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sarepta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : GNT0003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gene Therapy for Severe Crigler Najjar Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 15, 2018
Lead Product(s) : GNT0003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : X Vivo Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gene Therapy for X-linked Chronic Granulomatous Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 02, 2016
Lead Product(s) : X Vivo Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CD34+ Cell Transduced with WASP Lentiviral Vector
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 07, 2015
Lead Product(s) : CD34+ Cell Transduced with WASP Lentiviral Vector
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : X Vivo Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 16, 2013
Lead Product(s) : X Vivo Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable